Purple Biotech

Purple Biotech (NASDAQ:PPBT) is an innovative, clinical stage, oncology-focused company. We provide cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance.

Our pipeline includes two therapeutic oncology candidates, NT-219 and CM-24:

• NT-219 is a first-in-class, dual inhibitor small molecule targeting IRS 1/2 and STAT3, two key oncogenic drivers and drug resistance pathways. In pre-clinical studies, NT-219 demonstrated outstanding efficacy when administered both as a monotherapy or in combination with various oncology therapies. We have initiated first-in-human clinical trials with NT-219, both as monotherapy and in combination with cetuximab (Erbitux™), with plans to expand combination studies during 2021. Preliminary clinical data demonstrating a single-agent activity at the initial and the lowest dose level were presented at the 2021 ASCO annual meeting (download the ASCO slides here: //bit.ly/3z5GSGJ).
• CM-24 is a clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with high potential to treat multiple oncology indications. CEACAM1 is an inter-cellular adhesion regulator, TIM-3 activator, and is also associated with neutrophil extracellular traps and angiogenesis.

High CEACAM1 expression is known to be associated with poor disease prognosis in several tumor types. Thus, blocking CEACAM1 with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms. In a Phase I clinical study, CM-24 demonstrated a good safety profile and a promising efficacy signal. We are developing CM-24 in a clinical collaboration with Bristol Myers-Squibb. A Phase Ib/II trial combining CM-24 with nivolumab in NSCLC and pancreatic cancer patients expressing high CEACAM1 levels is on going. Preliminary clinical results demonstrating activity of CM24 in combination with nivolumab at the initial and the lowest dose level, were reported here- purple-biotech.com/Investors/#1Press